The protective effect of
KBT-3022 (ethyl 2-[4,5-bis-(4-methoxyphenyl)thiazol-2-yl]pyrrol-1-ylacetate) , a new
cyclooxygenase inhibitor, in
cerebral hypoxia and
ischemia was studied and compared with those of
indomethacin and
acetylsalicylic acid (ASA).
Oral administration of
KBT-3022 (3-100 mg/kg) and
indomethacin (3 and 10 mg/kg) significantly prevented KCN-induced death in mice, while ASA (100 mg/kg) had no effect.
KBT-3022 (3 and 10 mg/kg, p.o.) and
indomethacin (10 mg/kg, p.o.) significantly prolonged the survival time of mice subjected to normobaric
hypoxia, while ASA (100 mg/kg, p.o.) had no effect.
KBT-3022 (3-30 mg/kg, p.o.) and
indomethacin (3 mg/kg, i.p.) significantly ameliorated delayed neuronal death in the gerbil hippocampal CA1 sector after occlusion of bilateral carotid arteries for 5 min, while ASA (300 mg/kg, p.o.) had no effect.
KBT-3022 (10 mg/kg, p.o.) significantly inhibited
ATP depletion in the gerbil hippocampus after a 1-min occlusion of bilateral carotid arteries, but had no effect on
ATP depletion after a 5-min occlusion and the recovery during recirculation. These results show that
KBT-3022 exerts protective effects against
cerebral anoxia and
hypoxia and ameliorates delayed neuronal death in the hippocampus.
KBT-3022 may therefore be useful for prophylaxis of ischemic
cerebrovascular disorders.